Rebecca C. Coll, Kate Schroder, Pablo Pelegrín
Highlights
The nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing protein 3 (NLRP3) inflammasome is a key mediator of pathological inflammation in many diseases.
There are several drug-like small molecules under clinical development as novel therapeutics targeting the NLRP3 inflammasome.
Pyroptosis is a unique approach to suppress chronic inflammation.
Understanding the mechanism of action by which small molecules block the NLRP3 inflammasome allows better molecular optimization.
Different clinical trials are running using agents that inhibit the NLRP3 inflammasome.
Full review in:
Rebecca C. Coll, Kate Schroder, Pablo Pelegrín, NLRP3 and pyroptosis blockers for treating inflammatory diseases, Trends in Pharmacological Sciences, Volume 43, Issue 8, 2022, Pages 653-668, ISSN 0165-6147.
https://doi.org/10.1016/j.tips.2022.04.003
August, 2022
